Janaki Amin mainly investigates Internal medicine, Immunology, Hepatitis C virus, Virology and Viral load. He interconnects Gastroenterology, Surgery and Zidovudine in the investigation of issues within Internal medicine. His work deals with themes such as Mortality rate, Standardized mortality ratio, Confidence interval, Cause of death and Survival analysis, which intersect with Immunology.
Janaki Amin has included themes like Hepatocellular carcinoma, Cirrhosis and Hepatitis C in his Hepatitis C virus study. His study in Hepatitis C is interdisciplinary in nature, drawing from both Liver disease and Hepatitis B. His work investigates the relationship between Virology and topics such as Cohort that intersect with problems in Pre-exposure prophylaxis, Men who have sex with men, Drug and Prospective cohort study.
Janaki Amin mainly investigates Internal medicine, Immunology, Hepatitis C, Virology and Hepatitis C virus. His research in Internal medicine intersects with topics in Gastroenterology and Viral load. His study focuses on the intersection of Viral load and fields such as Regimen with connections in the field of Lopinavir and Confidence interval.
The Hepatitis C study combines topics in areas such as Epidemiology, Ribavirin, Sofosbuvir, Liver disease and Hepacivirus. His study in the fields of Virus and Coinfection under the domain of Virology overlaps with other disciplines such as Antibody-dependent cell-mediated cytotoxicity. His study looks at the relationship between Hepatitis C virus and topics such as Clinical trial, which overlap with Cirrhosis.
Janaki Amin spends much of his time researching Internal medicine, Hepatitis C, Hepatitis C virus, Virology and Incidence. His studies in Internal medicine integrate themes in fields like Drug and Sofosbuvir. His Hepatitis C research is multidisciplinary, incorporating elements of Pegylated interferon, Ribavirin and Liver disease.
His research integrates issues of Cirrhosis and Confidence interval in his study of Hepatitis C virus. His work in the fields of Virology, such as Viral load, intersects with other areas such as Practitioner research. As part of one scientific family, he deals mainly with the area of Incidence, narrowing it down to issues related to the Cohort, and often Emtricitabine, Pre-exposure prophylaxis, Rate ratio and Prospective cohort study.
His main research concerns Hepatitis C, Hepatitis C virus, Internal medicine, Virology and Cohort study. Janaki Amin works mostly in the field of Hepatitis C, limiting it down to topics relating to Liver disease and, in certain cases, Hepatitis, Risk factor and Public health. Hepatitis C virus is a subfield of Immunology that Janaki Amin investigates.
His Internal medicine research is mostly focused on the topic Clinical trial. When carried out as part of a general Virology research project, his work on Viral load is frequently linked to work in Government department and Antibody-dependent cell-mediated cytotoxicity, therefore connecting diverse disciplines of study. Janaki Amin has researched Viral load in several fields, including Gold standard, Venipuncture, Point-of-care testing and Hepacivirus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Reem Waziry;Behzad Hajarizadeh;Jason Grebely;Janaki Amin.
Journal of Hepatology (2017)
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
Jason Grebely;Kimberly A Page;Rachel Sacks-Davis;Martin Schim van der Loeff.
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Andrew Carr;Cassy Workman;Don E. Smith;Jennifer Hoy.
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.
Alison J. Rodger;Rebecca Lodwick;Mauro Schechter;Steven Deeks.
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Allison Martin;Don E Smith;Andrew Carr;Clare Ringland.
Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis
S Teeraananchai;SJ Kerr;SJ Kerr;J Amin;K Ruxrungtham.
Hiv Medicine (2017)
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
Janaki Amin;Matthew G Law;Mark Bartlett;John M Kaldor.
The Lancet (2006)
Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial
Allison Martin;Mark Bloch;Janaki Amin;David Baker.
Clinical Infectious Diseases (2009)
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Andrew E. Grulich;Rebecca Guy;Janaki Amin;Fengyi Jin.
The Lancet HIV (2018)
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Jason Grebely;Olav Dalgard;Brian Conway;Evan B Cunningham.
The Lancet Gastroenterology & Hepatology (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: